JP5567503B2 - 置換キサンチン誘導体 - Google Patents

置換キサンチン誘導体 Download PDF

Info

Publication number
JP5567503B2
JP5567503B2 JP2010548747A JP2010548747A JP5567503B2 JP 5567503 B2 JP5567503 B2 JP 5567503B2 JP 2010548747 A JP2010548747 A JP 2010548747A JP 2010548747 A JP2010548747 A JP 2010548747A JP 5567503 B2 JP5567503 B2 JP 5567503B2
Authority
JP
Japan
Prior art keywords
compound
deuterium
hydrogen
compounds
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010548747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513309A (ja
JP2011513309A5 (OSRAM
Inventor
ロジャー ディー． トゥン
ジュリー エフ． リュウ
スコット エル． ハーブソン
Original Assignee
コンサート ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンサート ファーマシューティカルズ インコーポレイテッド filed Critical コンサート ファーマシューティカルズ インコーポレイテッド
Publication of JP2011513309A publication Critical patent/JP2011513309A/ja
Publication of JP2011513309A5 publication Critical patent/JP2011513309A5/ja
Application granted granted Critical
Publication of JP5567503B2 publication Critical patent/JP5567503B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
JP2010548747A 2008-02-29 2009-02-27 置換キサンチン誘導体 Expired - Fee Related JP5567503B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US6773608P 2008-02-29 2008-02-29
US61/067,736 2008-02-29
US13456808P 2008-07-11 2008-07-11
US61/134,568 2008-07-11
US19871508P 2008-11-07 2008-11-07
US61/198,715 2008-11-07
PCT/US2009/001305 WO2009108383A2 (en) 2008-02-29 2009-02-27 Substituted xanthine derivatives

Publications (3)

Publication Number Publication Date
JP2011513309A JP2011513309A (ja) 2011-04-28
JP2011513309A5 JP2011513309A5 (OSRAM) 2012-04-12
JP5567503B2 true JP5567503B2 (ja) 2014-08-06

Family

ID=40600003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010548747A Expired - Fee Related JP5567503B2 (ja) 2008-02-29 2009-02-27 置換キサンチン誘導体
JP2010548745A Active JP5292413B2 (ja) 2008-02-29 2009-02-27 置換キサンチン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010548745A Active JP5292413B2 (ja) 2008-02-29 2009-02-27 置換キサンチン誘導体

Country Status (12)

Country Link
US (3) US20090239886A1 (OSRAM)
EP (3) EP2265334A2 (OSRAM)
JP (2) JP5567503B2 (OSRAM)
KR (1) KR20100121527A (OSRAM)
CN (1) CN101998957B (OSRAM)
AU (1) AU2009217680B2 (OSRAM)
BR (1) BRPI0908107A2 (OSRAM)
CA (1) CA2716788C (OSRAM)
EA (1) EA019088B1 (OSRAM)
MX (1) MX2010009300A (OSRAM)
WO (2) WO2009108375A1 (OSRAM)
ZA (1) ZA201006104B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5567503B2 (ja) 2008-02-29 2014-08-06 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
CN102159250B (zh) 2008-08-11 2014-08-06 尼克塔治疗公司 多臂的聚合烷酸酯偶联物
US20100087455A1 (en) * 2008-10-06 2010-04-08 Auspex Pharmaceuticals, Inc. Substituted xanthine compounds
US20100159034A1 (en) * 2008-12-15 2010-06-24 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
US20110053961A1 (en) * 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US9260432B2 (en) 2009-09-02 2016-02-16 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
JP2013503883A (ja) * 2009-09-02 2013-02-04 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
US9074233B2 (en) * 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
EP2611807A2 (en) * 2010-09-01 2013-07-10 Concert Pharmaceuticals Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione
US20140046060A1 (en) * 2010-09-01 2014-02-13 Concert Pharmaceuticals, Inc. Method of utilizing recycled deuterium oxide in the synthesis of deuterated compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012166459A1 (en) * 2011-05-27 2012-12-06 Bristol-Myers Squibb Company Tripeptides incorporating deuterium as inhibitors of hepatitis c virus
WO2013013052A1 (en) * 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物
US20150087660A1 (en) * 2012-05-10 2015-03-26 Mahesh Kandula Compositions and methods for the treatment of chronic diseases and inflammatory disorders
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
CN106456647A (zh) * 2014-04-18 2017-02-22 康塞特医药品有限公司 治疗高血糖症的方法
WO2015175008A1 (en) * 2014-05-14 2015-11-19 Concert Pharmaceuticals, Inc. Methods of treating chronic kidney disease characterized by macroalbuminuria
WO2017058881A1 (en) 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
WO2017071606A1 (zh) * 2015-10-29 2017-05-04 南京明德新药研发股份有限公司 羟基嘌呤类化合物的医药用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2330742C2 (de) 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
JPS5576876A (en) 1978-12-05 1980-06-10 Grelan Pharmaceut Co Ltd Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne
JPS55122779A (en) 1979-03-13 1980-09-20 Maruko Seiyaku Kk Preparation of theobromine derivative
CS201558B1 (en) 1979-05-14 1980-11-28 Pavol Kovar Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine
JPS567785A (en) 1979-07-02 1981-01-27 Maruko Seiyaku Kk Preparation of theobromine derivative
JPS5610187A (en) 1979-07-05 1981-02-02 Grelan Pharmaceut Co Ltd Separation and purification of 1-(5-oxohexyl)- 3,7-dimethylxanthine
JPS5610188A (en) 1979-07-06 1981-02-02 Dainippon Ink & Chem Inc Xanthine derivative and its preparation
JPS5632477A (en) 1979-08-27 1981-04-01 Nippon Iyakuhin Kaihatsu Kenkyusho:Kk Preparation of 1- 5-oxohexyl -3,7-dimethylxanthine
JPS5677279A (en) 1979-11-28 1981-06-25 Ota Seiyaku Kk Preparation of xanthine derivative
JPS5711981A (en) 1980-06-26 1982-01-21 Sagami Chem Res Center Theobromine derivative and its preparation
JPS5724386A (en) 1980-07-17 1982-02-08 Nissan Chem Ind Ltd Preparation of xanthine derivative
JPS5724385A (en) 1980-07-17 1982-02-08 Nissan Chem Ind Ltd Theobromine derivative and its preparation
JPS5724382A (en) 1980-07-17 1982-02-08 Nissan Chem Ind Ltd Trithiane derivative and its preparation
JPS5756481A (en) 1980-09-22 1982-04-05 Kawashima Yakuhin Kaihatsu Kk Production of 1-(5-oxohexyl)-3,7-dimethylxanthine
JPS5762278A (en) 1980-10-01 1982-04-15 Sagami Chem Res Center Theobromine derivative and its preparation
JPS5780385A (en) 1980-11-05 1982-05-19 Mitsubishi Petrochem Co Ltd Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine
JPS5785387A (en) 1980-11-14 1982-05-28 Teikoku Chem Ind Corp Ltd Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine
JPS5798284A (en) 1980-12-10 1982-06-18 Kawashima Yakuhin Kaihatsu Kk Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine
JPS57200391A (en) 1981-06-02 1982-12-08 Daito Koeki Kk 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine
JPS5838284A (ja) 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd １−（５′−オキソヘキシル）−３，７−ジメチルキサンチンの製造方法
JPS58134092A (ja) 1982-02-05 1983-08-10 Sagami Chem Res Center テオブロミン誘導体
JPS58150594A (ja) 1982-03-03 1983-09-07 Daito Koeki Kk キサンチン誘導体の製造方法
CS237719B1 (cs) 1983-05-12 1985-10-16 Jan Jendrichovsky SpAsob přípravy dimetyl-(5-oxohexyl)-xantlnov
DE3508097A1 (de) 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
DD274334A3 (de) 1985-12-17 1989-12-20 Dresden Arzneimittel Verfahren zur herstellung von reinem 3,7-dimethyl-1-(5-oxohexyl)-xanthin
IL100533A (en) 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical preparations containing a history of xanthine for VIH treatment and disease states
CS263595B1 (sk) 1988-01-06 1989-04-14 Rybar Alfonz Spdsob pripravy 7-n-prnpyl-3-metyl 3,7-dihydro-lH-purín-2,6-dionu
JP2661666B2 (ja) 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
IT1231779B (it) 1989-08-09 1991-12-21 Eniricerche Spa Procedimento per l'ossidazione di composti paraffinici.
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
DE3942872A1 (de) 1989-12-23 1991-06-27 Hoechst Ag Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
AU9084991A (en) 1990-11-01 1992-05-26 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
DK0484785T3 (da) 1990-11-07 1996-09-23 Hoechst Marion Roussel Inc Anvendelse af xanthiner til fremstilling af et lægemiddel, der er virksomt til inhibering af formeringen af humane retrovira
IL100195A0 (en) 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
IL100194A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
US5763446A (en) 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
HUT68560A (en) 1993-08-02 1995-04-27 Chinoin Gyogyszer Es Vegyeszet The use of xantine derivatives for promotion of healing of operative lesions
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
EP0759915B1 (en) 1994-05-16 2002-10-16 Cell Therapeutics, Inc. Asymmetric synthesis of chiral secondary alcohols
AU3539795A (en) 1994-08-25 1996-03-14 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
DE4430128A1 (de) 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19544768C1 (de) 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6248889B1 (en) 1998-11-20 2001-06-19 3M Innovative Properties Company Process for converting an alcohol to the corresponding fluoride
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6417208B1 (en) 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
US6316458B1 (en) * 1999-04-30 2001-11-13 Cell Therapeutics, Inc. Method of enhancing insulin action
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
GB0102107D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
BR0209325A (pt) 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2003013568A1 (en) 2001-08-02 2003-02-20 Ortho-Mcneil Pharmaceutical, Inc. Cytokine modulation therapy
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
AU2003220342B2 (en) 2002-03-14 2007-06-07 Bayer Pharmaceuticals Corporation Methods of treating diabetes using PDE 11A inhibitors
DE10214228A1 (de) 2002-03-22 2003-10-02 Bdd Group Holding Ag Zug Deuterierte substitutierte Indole sowie diese Verbindungen enthaltende Arzneimittel
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
TW200510407A (en) 2003-06-30 2005-03-16 Altana Pharma Ag Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
WO2005023193A2 (en) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methods of treating endometriosis
WO2005120514A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20080020018A1 (en) 2004-09-27 2008-01-24 Joey Moodley Combination Products
KR20070083839A (ko) 2004-09-29 2007-08-24 코디스 코포레이션 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태
BRPI0617987A2 (pt) 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
JP5567503B2 (ja) 2008-02-29 2014-08-06 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
US8263601B2 (en) * 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
US20110053961A1 (en) * 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8485557B2 (en) 2009-08-27 2013-07-16 Kermit Zarley Enterprises Self-supporting book
JP2013503883A (ja) * 2009-09-02 2013-02-04 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体

Also Published As

Publication number Publication date
MX2010009300A (es) 2010-11-05
AU2009217680A1 (en) 2009-09-03
EP2265334A2 (en) 2010-12-29
WO2009108383A2 (en) 2009-09-03
EP3199203A1 (en) 2017-08-02
US20140121226A1 (en) 2014-05-01
US20150322068A1 (en) 2015-11-12
JP2011513309A (ja) 2011-04-28
JP5292413B2 (ja) 2013-09-18
EP2265612A1 (en) 2010-12-29
EA201001391A1 (ru) 2011-08-30
AU2009217680B2 (en) 2013-09-05
ZA201006104B (en) 2012-01-25
CA2716788A1 (en) 2009-09-03
US9035050B2 (en) 2015-05-19
CN101998957B (zh) 2013-06-05
BRPI0908107A2 (pt) 2019-09-24
CA2716788C (en) 2016-08-16
WO2009108383A3 (en) 2009-10-22
CN101998957A (zh) 2011-03-30
KR20100121527A (ko) 2010-11-17
EP2265612B1 (en) 2017-04-05
EP3199203B1 (en) 2020-02-05
EA019088B1 (ru) 2014-01-30
JP2011513307A (ja) 2011-04-28
WO2009108375A1 (en) 2009-09-03
US20090239886A1 (en) 2009-09-24
US9493463B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
JP5567503B2 (ja) 置換キサンチン誘導体
JP5292516B2 (ja) 置換キサンチン誘導体
US10335413B2 (en) Substituted xanthine derivatives
JP2013503883A (ja) 置換キサンチン誘導体
HK1170377B (en) Substituted xanthine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131030

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140619

R150 Certificate of patent or registration of utility model

Ref document number: 5567503

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees